

Curriculum vitae

Date Prepared: April 4, 2022

Name: Mack Clarence Mitchell, Jr., M.D.



Office Address: Department of Internal Medicine
University of Texas Southwestern Medical Center
5323 Harry Hines Blvd.
B9
Dallas, TX, 75390
Tel: 214-648-5036
FAX: 214-648-5607
Email: mack.mitchell@utsouthwestern.edu

Place of Birth: Salzburg, Austria

Education

B.A. Human Biology Davidson College, Davidson, NC
M.D. Johns Hopkins University, Baltimore, MD
Johns Hopkins School of Medicine, Baltimore, MD

Postdoctoral Training

| | | |
|------------|---|---|
| Internship | Johns Hopkins Hospital, Baltimore, Maryland | Internal Medicine |
| Residency | Johns Hopkins Hospital, Baltimore, Maryland | Internal Medicine |
| Fellowship | Johns Hopkins School of Medicine, Baltimore | Hepatology |
| Fellowship | Vanderbilt University School of Medicine | Gastroenterology and Clinical Pharmacology |

Licensure: Maryland Medical License - 1980-1996, 2003-2013
Texas Medical License – 2011-

Board and Other Certification:

National Board of Medical Examiners, 1978
American Board of Internal Medicine, Diplomate 1981 (Lifetime)
American Board of Internal Medicine, Gastroenterology, Diplomate 1985 (Lifetime)
American Board of Internal Medicine, Maintenance of Certification, Gastroenterology 2008 (voluntary)

Honors and Awards

Phi Eta Sigma Freshman Honorary Fraternity, Davidson College
Freshman Chemistry Award, Davidson College
Phi Beta Kappa, Johns Hopkins University
Alpha Omega Alpha, Johns Hopkins School of Medicine
American Liver Foundation Research Fellowship
National Research Service Award
American Gastroenterology Association Interdisciplinary Award
New Investigator Award, NIAAA (AA06865)
Fellowship American College of Physicians

Fellowship American College of Gastroenterology
 Teaching Award, Greater Baltimore Medical Center
 Voted one of Baltimore's Best physicians, annually 1991-1995
 Voted one of Best Doctors in America 1995-2003, 2009-2015
 Seixas Award for Distinguished Service, Research Society on Alcoholism
 D-Magazine Best Doctors 2014-2017
 Fellowship American Association for the Study of Liver Diseases

Faculty Academic Appointments

| | | |
|--------------|---|---|
| 1982-1989 | Assistant Professor of Medicine | The Johns Hopkins University School of Medicine |
| 1989-1996 | Associate Professor of Medicine | The Johns Hopkins University School of Medicine |
| 1996-2003 | Clinical Professor of Medicine | University of North Carolina |
| 2004-2011 | Associate Professor of Medicine | The Johns Hopkins University School of Medicine |
| 2011-present | Professor of Internal Medicine | University of Texas Southwestern Medical Center |
| 2017-present | Nancy S. and Jeremy L. Halbreich Professor of Gastroenterology | University of Texas Southwestern Medical Center |

Appointments at Hospitals/Affiliated Institutions

Medical staff at Parkland Memorial Hospital and Clements University Hospital

Other Professional Positions

| Year(s) | Position Title | Institution |
|--------------|----------------|--|
| 1989-Present | President | ABMRF, The Foundation for Alcohol Research |

Major Administrative/Leadership Positions

| | | |
|--------------|--|---|
| 1991-1996 | Chairman of Internal Medicine | Greater Baltimore Medical Center |
| 1991-1993 | Program Director of Internal Medicine | Greater Baltimore Medical Center |
| 1996-2003 | Chairman of Medicine | Carolinas Medical Center, Charlotte, NC |
| 2004-2008 | Program Director of Gastroenterology | Johns Hopkins Bayview Medical Center |
| 2004-2010 | Chief of Gastroenterology | Johns Hopkins Bayview Medical Center |
| 2009-2011 | Medical Director of Ambulatory Services | Johns Hopkins Bayview Medical Center |
| 2011-2016 | Vice Chairman Clinical Operations Department of Internal Medicine | University of Texas Southwestern Medical Center |
| 2016-2017 | Executive Vice Chairman Department of Internal Medicine | University of Texas Southwestern Medical Center |
| 2015-2016 | Associate Vice President for Population Health | University of Texas Southwestern Medical Center |
| 2015-2016 | Chief Medical Officer | UT Southwestern Accountable Care Network |
| 2016-2020 | Chief Medical Officer | Southwestern Health Resources Physician Network |
| 2017-2018 | Executive Vice President Health System Affairs (Interim) | University of Texas Southwestern Medical Center |
| 2016-present | Vice-President for Medical Affairs | University of Texas Southwestern Medical Center |

Committee Service (Member, unless noted otherwise)

| Year(s) | Name of Committee | Institution/Organization |
|---|--|--------------------------|
| <u>UT Southwestern Medical Center</u> | | |
| 2011 – 2018 2014 - 2018 | Managed Care Contracting Committee Chairman | UT Southwestern |
| 2011 - 2016 | Transplant Advisory Committee | UT Southwestern |
| 2011 - 2020 | Outcomes, Quality & Safety Committee | UT Southwestern |
| 2011 – 2020 | 2012-2018 Six-Year Plan Clinical Support Services Committee | UT Southwestern |
| 2012-Present | OSC Steering Committee | UT Southwestern |
| 2013-2016 | Board Member UT Southwestern Accountable Care Network | UT Southwestern |
| 2013- Present | Health System IR Committee | UT Southwestern |
| 2017-2020 | Board Member, Southwestern Health Resources | UT Southwestern |
| 2019-Present | Chair, Professional Liability Committee | UT Southwestern |
| 2019-Present | Chair, Medical Group Compliance Committee | UT Southwestern |
| 2019-Present | Chair, Institutional Travel Oversight Committee | UT Southwestern |
| <u>Johns Hopkins University School of Medicine</u> | | |
| 1982-1990 | Internship selection committee | Johns Hopkins University |
| 1982-1988 | Internship Subcommittee Chairman | Johns Hopkins Hospital |
| 1983-1984 | Ad hoc committee on research and faculty development | Johns Hopkins University |
| 1986-1987 | Ad hoc committee on Internal Medicine Residency | Johns Hopkins University |
| 1986-1987 | Ad hoc committee on curriculum on alcohol education | Johns Hopkins University |
| 1989-1993 | Medical student advisor | Johns Hopkins University |
| 2004-2011 | Admissions Committee, JHU School of Medicine | Johns Hopkins University |
| 2007-2011 | Contracting Committee, Clinical Practice Assoc. | Johns Hopkins University |
| 2009-2011 | Management Committee, Clinical Practice Assoc. | Johns Hopkins University |

Professional Societies

| Dates | Society Name, member |
|--------------|---|
| 1982-Present | American Association for Study of Liver Diseases |
| 1987-Present | American College of Physicians (Fellow) |
| 1982-Present | Johns Hopkins Medical and Surgical Association |
| 1984-89 | American Federation for Clinical Research (Eastern Section Councilor) |
| 1986-Present | Research Society on Alcoholism |

Grant Review and External Committee Activities

| Year(s) | Name of Review Committee |
|-----------|---|
| 1984-1988 | Biomedical research council member, ABMRF |

| | |
|--------------|--|
| 1988 | NIAAA ad hoc member Biomedical-1 review group |
| 1988 | NIAAA ad hoc study section for alcohol research centers |
| 1988-1991 | VA Merit Review Board on Alcohol & Clinical Pharmacology |
| 1989-1993 | NIAAA Biomedical-1 review group |
| 1990 | VA ad hoc review board for Alcohol Research Centers |
| 1992-1996 | Governor's Council (Maryland), American College of Physicians |
| 1991-1994 | AASLD Research Committee |
| 1995 | Chairman, NIAAA Alcohol Research Centers Grant Review Committee |
| 2003 | Member of search committee for Director of NIAAA |
| 2004-2008 | Member of examination pre-test committee, American Board of Internal Medicine |
| 2005-2008 | National Advisory Council, NIAAA |
| 2009- | Extramural Advisory Board, NIAAA |
| 2010-2014 | Chair, ad hoc examination committee, American Board of Internal Medicine |
| 2016-2021 | Board of Scientific Counselors, National Institute of Alcoholism and Alcohol Abuse (NIAAA) |
| 2020-2021 | Chair, Board of Scientific Counselors, NIAAA |
| 2016-Present | Board of Directors, Amygdala Neurosciences |
| 2018-2021 | Practice Management and Economics Committee, American Gastroenterology Assoc. |
| 2018-2020 | Board of Directors, Care N' Care Insurance Company |
| 2021 | NIDDK, ad hoc study section for Liver Cirrhosis Research Network Clinical Centers |

Editorial Activities

| Year(s) | Journal Name |
|-------------------------------|--|
| <u>Editorial Board</u> | |
| 1989-1995 | <i>Hepatology</i> |
| 1990-1995 | <i>Alcoholism, Clinical and Exp Research</i> |
| 2005-2010 | <i>Alcoholism, Clinical and Exp Research</i> |
| <u>Ad Hoc Reviewer</u> | |
| | <i>Hepatology, Gastroenterology, Annals of Internal Medicine, Digestive Diseases and Sciences, Medicine, American Journal of Physiology, American Journal Clinical Nutrition, Alcoholism: Clinical & Experimental Research, Journal of Clinical Investigation, Journal of Clinical Gastroenterology and Hepatology</i> |

Grant Support

Extramural funding:

| | |
|-----------------------|--|
| <u>Present</u> | Alcoholic Hepatitis: Clinical and Translational Late Phase Clinical Trials and Observational Studies U01 AA 026975 \$1,840,860 direct costs PI: Mack C. Mitchell, MD 2018-2023 |
|-----------------------|--|

| | |
|-------------|--|
| | <p>STOP-ALF Study, multicenter trial of ornithine phenylacetate for acute liver failure due to acetaminophen overdose PI: William Lee, MD External data safety monitor: Mack C. Mitchell, MD 2011-Present</p> |
| <u>Past</u> | <p>Novel Therapies in Alcoholic Hepatitis U01 AA021893 \$10,000,000 direct costs PI: Gyongi Szabo, MD, PhD Site Principal Investigator for UTSW: Mack C. Mitchell, MD 2012-2018</p> |
| | <p>National Research Service Award NIDDK \$29,000 direct costs; support for postdoctoral research fellowship PI: M.C. Mitchell ; 90% effort 1980-1982</p> |
| | <p>Studies on benoxaprofen metabolism. Eli Lilly Company \$45,000 direct costs PI: M.C. Mitchell ;10% effort 1982</p> |
| | <p>Core support for alcohol research center ABMRF \$900,000 direct costs M.C. Mitchell and E. Mezey, Co-PI Dr. Mitchell was P.I. from 1982-1984, co-PI from 1984-1988; 25% effort 1982-1988</p> |
| | <p>Effects of ethanol on glutathione turnover American Gastroenterological Association \$50,000 direct costs PI: M.C. Mitchell; 25% effort 1983-1984</p> |
| | <p>Effects of H₂-receptor antagonists on acetaminophen metabolism in alcoholic rats Smith-Kline \$40,510 direct costs PI: M.C. Mitchell, 10% effort 1988-1989</p> |
| | <p>Effects of ethanol on glutathione metabolism R23 AA-06865 NIAAA \$102,500 direct costs PI: M.C. Mitchell; 50% effort 1985-1988</p> |
| | <p>Effects of ethanol on glutathione metabolism RO1 AA-06865 NIAAA \$318,028 direct costs; PI: M.C. Mitchell; 30% effort 1988-1991</p> |

| | |
|--|---|
| | Alcohol training grant T32 AA07567 E. Mezey, P.I. Co-investigator, 10% effort 1987-1991 Jane Dees and David Raiford were trainees under Dr. Mitchell's supervision |
| | Liver Disease and HIV-HBV co-infection in the HAART era RO1 AI-060449 NIAID \$463,368 direct costs PI: Chloe Thio M.C. Mitchell, consultant; performed liver biopsies and advised on results, 1% effort 2004-2011 |
| | RESTORE study to evaluate endoscopic revision of gastric bypass surgery Davol, Inc (Bard Surgical Specialties) \$317,137 direct costs PI: Michael Schweitzer, MD M.C. Mitchell, co-investigator; performed all endoscopies and performed endoscopic revision of gastric bypass with Dr. Schweitzer 2007-2010 |
| | Paion CNS 7056-002 study to evaluate a novel benzodiazepine for conscious sedation in colonoscopy. Parexel Clinical Trials Unit \$48,000 direct costs PIs: Mack C. Mitchell, Mark Worthington and Laurie Antonik 2009-2010 |

Clinical Trials Activities

| | |
|----------------|--|
| <u>Present</u> | Novel Therapies in Alcoholic Hepatitis U01 AA021902-01 Studies on Patients with Severe Acute Alcoholic Hepatitis Studies on Patients with Moderately Severe Acute Alcoholic Hepatitis |
| <u>Past</u> | Glaxo-Smith Kline Lamivudine in treatment of chronic hepatitis B, Phase 2A PI: Mack C. Mitchell |

Teaching Activities

| Year(s) | Activity |
|------------------------------|---|
| <u>Classroom instruction</u> | |
| 1982-1991 | Lectures in pathophysiology course |
| 1985-1989 | Lectures on Alcohol in Biochemical Nutrition course |
| 1986-1990 | Lectures on Alcohol in Biochemistry Course |
| 1983-1995 | Lecture on gastrointestinal drugs, Pharmacology course |
| 1986-1995 | Lecture on alcohol, Pharmacology course |
| 2004-2011 | Lecture on hepatic drug metabolism, Pharmacology course |

| | |
|---|---|
| 2008-2011 | Lecture on alcoholic and non-alcoholic fatty liver disease, Pathophysiology |
| 1986 | Lecture on occupational liver disease |
| 1987 | Lecture on medical consequences of alcoholism |
| <u>Clinical Instruction</u> | |
| 1982-1984 | Attending instructor for Clinical Skills |
| 1985 | Attending on basic medicine clerkship |
| 1986 | Attending on Osler advanced medicine clerkship |
| 1987 | Attending on Osler advanced medicine clerkship |
| 1988-1993 | Instructor for Clinical Skills |
| 1993-1994 | Instructor for Physical Diagnosis, U. of Md |
| 1995 | Attending on Nelson/Baker service Johns Hopkins |
| 1996-2002 | Attending on basic medicine clerkship for UNC students |
| 2004-2011 | Preceptor for ambulatory clinics in gastroenterology |
| <u>Mentoring</u> | |
| <i>Preceptor for Medical Student Research Electives</i> | |
| 1984 | Sebastian Morton (Private Practice, Pathology, Florida) |
| 1985 | Jeff Pierson (Private practice, Orthopedic Surgery, Indiana) |
| 1985 | David Raiford (Professor of Medicine, Vice-Chancellor Faculty Affairs, Vanderbilt University) |
| 1986 | David Callans (Professor of Medicine, Univ Pennsylvania) |
| 1986 | Rod Owens (Private practice, Radiology, Arizona) |
| 1987 | Kathy Maletic Neuzil (Professor of Medicine, U. Maryland) |
| 1988 | Dan Pratt (Professor of Medicine, Harvard University) |
| 1989 | Ian Flinn (Associate Professor of Oncology, Johns Hopkins) |
| 1989 | Sarah Streett (Associate Professor of Medicine, Stanford University) |
| 1989 | Jerry Boley (Private practice, Cardiology, Ohio) |
| 1990 | Jeffrey Caddedu (Professor of Urology, UT Southwestern) |
| <i>Preceptor for Postdoctoral Research Fellows:</i> | |
| 1987-1988 | Ariane Mallat, M.D., Professor of Medicine and Pharmacology, Hopital Henri Mondor, Creteil France |
| 1988 | Jane Dees, Ph.D., University of Maryland, Department of Pharmacology |
| 1989-1990 | Marc Litt, M.D., (Private practice, Cardiology, Jacksonville, FL) |
| 1989-1991 | David Raiford, M.D., Vanderbilt University, Vice-Chancellor for Academic Affairs, Professor of Medicine |

| Year(s) | Title | Location |
|---------|---|---------------------|
| 1982 | Eli Lilly Company, Benoxaprofen toxicity symposium | |
| 1983 | American Society of Clinical Pharmacology, Symposium on NSAID toxicity | San Diego, CA |
| 1984 | University of Maryland Medical School, Research Seminar | Baltimore, MD |
| 1985 | International Medical Advisory Conference on Alcohol, Turnberry, Scotland | Turnberry, Scotland |
| 1986 | University of Maryland Medical School, Research Seminar | Baltimore, MD |

| | | |
|------|--|---------------------|
| 1987 | Research Society on Alcoholism, Symposium on Alcohol and Drug Toxicity | Philadelphia, PA |
| 1988 | Wayne State University, Research Seminar and Lecture | Detroit, MI |
| 1988 | Phoenix Gastroenterology Society & VA Medical Center, Guest lecturer | Phoenix, AZ |
| 1988 | Vanderbilt School of Medicine, Research Seminar | Nashville, TN |
| 1989 | NIH/NHLBI Research Seminar | Bethesda, MD |
| 1989 | University of Virginia, Guest Lecturer and Research Seminar | Charlottesville, VA |
| 1989 | Medical University of South Carolina, Visiting Professor, Research Seminar | Charleston, SC |
| 1990 | Gordon Research Conference on Alcohol, Invited Speaker | Santa Barbara, CA |
| 1990 | INSERM, Hospital Henri Mondor, Paris, Research Seminar | Paris, France |
| 1991 | SUNY, Stony Brook, Medical Grand Rounds | Long Island, NY |
| 1992 | Alcohol, AIDS and Immunomodulation, Tucson, AZ, Invited Speaker | Tucson, AZ |
| 1992 | AASLD Annual Postgraduate Course, Invited Speaker | Chicago, IL |
| 1993 | University of Virginia, Guest Lecturer for Nutrition Symposium | Charlottesville, VA |
| 1996 | American College of Gastroenterology, Regional Postgraduate Course | Annapolis, MD |
| 1997 | American College of Gastroenterology, Marcel Patterson Memorial Lecture | Galveston, TX |
| 2001 | Canadian Association of Gastroenterology Symposium on Hepatitis B | Calgary, CN |
| 2006 | Peruvian Society of Gastroenterology, Keynote Speaker | Lima, Peru |
| 2007 | AGA Institute, Symposium on Hepatitis B, Invited Speaker | Bethesda, MD |
| 2007 | American College of Gastroenterology Regional Postgraduate Course, Invited Speaker | Williamsburg, VA |
| 2008 | Wasserman Lecture, Sinai Hospital | Baltimore, MD |
| 2008 | International Symposium on Alcoholic Liver Disease and Cirrhosis, Invited Speaker | Bilbao, Spain |
| 2008 | UT San Antonio Health Science Center, Visiting Professor | San Antonio, TX |
| 2009 | Digestive Disease Week, Current Concepts in Cirrhosis Management, Session chair | Chicago, IL |
| 2009 | Hepatitis B Foundation Annual Meeting; Keynote speaker | Philadelphia, PA |
| 2009 | Stella Levin Lecture and Visiting Professor, Wake Forest School of Medicine | Winston Salem, NC |
| 2010 | Wake Forest School of Medicine, CME course | Winston Salem, NC |
| 2012 | Visiting professor, MD Anderson Cancer Center | Houston, TX |
| 2012 | Research seminar, Waggoner Center, Univ of Texas | Austin, TX |
| 2012 | Visiting professor, Carolinas Medical Center | Charlotte, NC |
| 2013 | Visiting professor, Lankenau Hospital | Philadelphia, PA |
| 2013 | Organizer and speaker, Advances for Practitioners, AASLD annual meeting | Washington, DC |
| 2013 | Grand Rounds, Presbyterian Hospital | Dallas, TX |
| 2014 | Visiting professor, Johns Hopkins Bayview Med Ctr | Baltimore, MD |
| 2014 | Invited speaker, Research symposium in honor of Ray Burk, Vanderbilt University Med Center | Nashville, TN |

| | | |
|------|---|-------------------------|
| 2015 | AASLD Mid-Year CME course | Chicago, IL |
| 2016 | AASLD Emerging Trends in Alcoholic Hepatitis | Miami, FL |
| 2016 | Best of EASL and DDW, Temple University | Philadelphia, PA |
| 2017 | Wu Jieping Medical Foundation, Keynote speaker | Beijing, China |
| 2017 | Visiting professor, Lankenau Hospital | Philadelphia, PA |
| 2018 | FDA, Invited speaker on Alcoholic Hepatitis | Washington, DC |
| 2018 | RSA Symposium, Design of trials for alcoholic hepatitis | San Diego, CA |
| 2018 | Visiting professor, Univ of Miami GI Division | Miami, FL |
| 2018 | Invited speaker, High Value Care Academic Alliance | Baltimore, MD |
| 2019 | Invited speaker, Clinical Overview of Alcohol-associated Liver Disease, NIAAA-NIDDK symposium | Bethesda, MD |
| 2019 | Invited speaker, Alcohol-associated Cirrhosis & Fibrosis: Research Opportunities and Needs, AASLD-EASL symposium | Chicago, IL |
| 2020 | Invited speaker, Rethinking management of alcohol-associated liver disease, AASLD Postgraduate Course | On-line due to COVID-19 |
| 2020 | Invited speaker, Disease definitions and clinical studies in alcohol-associated hepatitis. NIAAA research symposium | On-line due to COVID-19 |
| 2021 | Invited Speaker, Pathogenesis of alcohol-associated hepatitis. Johns Hopkins DELTA Center for Alcohol Research Symposium. | On-line due to COVID-19 |

Bibliography

Peer-Reviewed Publications

Original Research Articles

1. **Mitchell MC**, Williams GM. Platelet mixed agglutination: A sensitive method for detecting HL-A and non-HL-A antigens. *Surgical Forum* 1974; 25:194-196.
2. **Mitchell MC**, Mezey E, Maddrey WC. Effects of variation in dietary protein and ethanol on hepatic microsomal drug metabolism in the rat. *Hepatology* 1981; 1:336-340.
3. **Mitchell MC**, Schenker S, Avant GR, Speeg KV. Cimetidine protects against acetaminophen hepatotoxicity in the rat. *Gastroenterology* 1981; 81:1052-1060.
4. **Mitchell MC**, Boitnott J, Kauffman S, Cameron JL, Maddrey WC. Hepatic vein occlusion: The Budd-Chiari syndrome. *Medicine* 1982; 61:199-218.
5. Speeg KV, Patwardhan RV, Avant GR, **Mitchell MC**, Schenker S. Inhibition of microsomal drug metabolism by histamine H₂-receptor antagonists studied *in vivo* and *in vitro* in rodents. *Gastroenterology* 1982; 82:89-96.
6. **Mitchell MC**, Hoyumpa A, Schenker S, Patwardhan RV. Differential effects of chronic ethanol feeding on cytochrome P-448 and P450 mediated drug metabolism in the rat. *Biochem. Pharmacol.* 1982; 31:695-699.
7. **Mitchell MC**, Boitnott J, Kauffman S, Cameron JL, Maddrey WC. Hepatic vein occlusion: The Budd-Chiari syndrome. *Medicine* 1982; 61:199-218.

8. Patwardhan RV, **Mitchell MC**, Johnson RF, Schenker S. Differential effects of oral contraceptive steroids on the metabolism of benzodiazepines. *Hepatology* 1983; 3:248-253.
9. **Mitchell MC**, Hoyumpa AM, Schenker S, Johnson RF, Nichols S, Patwardhan RV. Inhibition of caffeine elimination by short-term ethanol administration. *J. Lab. Clin. Med.* 1983; 101:826-834.
10. **Mitchell MC**, Hainew T, Meredith CM, Schenker S. Effects of oral contraceptive steroids on acetaminophen metabolism and elimination. *Clin. Pharmacol. Ther.* 1983; 34:48-53.
11. **Mitchell MC**, Schenker S, Speeg KV Jr. Selective inhibition of acetaminophen oxidation and toxicity by cimetidine and other Histamine H₂-receptor antagonists *in vivo* and *in vitro* in the rat and in man. *J. Clin. Invest.* 1984; 73:383-391.
12. Morton S, **Mitchell MC**. The effects of chronic ethanol feeding on glutathione turnover in the rat. *Biochem. Pharmacol.* 1985; 34:1559-1563.
13. Speeg KV, **Mitchell MC**, Maldonado AL. Additive protection of cimetidine and N-acetylcysteine treatment against acetaminophen induced hepatic necrosis in the rat. *J. Pharmacol. Exp. Ther.* 1985; 234:550-554.
14. Pierson J, **Mitchell MC**. Increased hepatic efflux of glutathione after chronic ethanol feeding. *Biochem. Pharmacol.* 1986; 35:1533-1537.
15. **Mitchell MC**, Herlong HF. Alcohol and nutrition: Caloric value, bioenergetics, and relationship to liver damage. *Ann. Rev. Nutr.* 1986; 6:457-474.
16. Diehl AM, **Mitchell MC**, Herlong HF, Potter JJ, Wacker LS, Mezey E. Changes in plasma amino acids during sobriety in alcoholic patients with and without liver disease. *Am. J. Clin. Nutr.* 1986; 44:453-460.
17. Callans DJ, Wacker LS, **Mitchell MC**. Effects of ethanol feeding and withdrawal on plasma glutathione elimination in the rat. *Hepatology* 1987; 7:496-501.
18. Scott R, **Mitchell MC**. Aging, alcohol and the liver. *J. Am. Geriatric Soc.* 1988; 36:255-265.
19. Mezey E, Kolman CJ, Diehl AM, **Mitchell MC**, Herlong HF. Alcohol and dietary intake in the development of chronic pancreatitis and liver disease in alcoholism. *Am. J. Clin. Nutr.* 1988; 48:148-151.
20. **Mitchell MC**, Hall SD, Schenker S, Branch RA. Impaired hepatic elimination of paracetamol and its metabolites in the rat following chronic ethanol pretreatment. *Alcoholism: Clin. Exp. Res.* 1989; 13:264-270.
21. Ambrosio G, Jacobus WE, **Mitchell MC**, Litt MR, Becker LC. Effects of ATP precursor administration on ATP and "free" ADP content and on recovery of contractility in post-ischemic stunned hearts. *Am. J. Physiol.* 1989; 256:H560-6.
22. **Mitchell MC**, Hamilton R, Wacker LS, Branch RA. Zonal distribution of paracetamol glucuronidation in the isolated perfused rat liver. *Xenobiotica* 1989; 19:389-400.
23. Burdick JF, Colombani PM, Pitt HA, Perler BA, Merritt WT, Crandall BC, **Mitchell MC**, Herlong HF and Williams GM. Overcoming early cyclosporine nephrotoxicity after liver transplantation. *Transplantation Proceedings* 1989; 21:2236-2237.

24. Sitzman JV, Bulkley G, **Mitchell MC**, Campbell K. Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension. *Ann. Surg.* 1989; 209:322-7.
25. Litt M, Potter JJ, Mezey E, **Mitchell MC**. Analysis of pyridine dinucleotides in cultured rat hepatocytes by high-performance liquid chromatography. *Anal. Biochem.* 1989; 179:34-36.
26. Mullin GE, Greenson JK, **Mitchell MC**. Fulminant hepatic failure after ingestion of sustained release nicotinic acid. *Ann. Int. Med.* 1989; 111:253-255.
27. Felver ME, Mezey E, McGuire M, **Mitchell MC**, Herlong HF, Veech GA, Veech RL. Plasma tumor necrosis factor predicts decreased long-term survival in severe alcoholic hepatitis. *Alcoholism: Clin. & Exp. Res.* 1990; 14:255-59.
28. **Mitchell MC**, Mallat A, Lipsky JL. Cephalosporin-induced alteration in hepatic glutathione redox state. A potential mechanism for inhibition of hepatic reduction of vitamin K₁, 2,3-epoxide in the rat. *J. Clin. Invest.* 1990;86:1589-1594.
29. Buescher PC, Pearse DB, Pilla RP, Litt MR, **Mitchell MC**, Sylvester JT. Energy state and vasomotor tone in hypoxic pig lungs. *J. Appl. Physiol.* 1991;70:1874-1881.
30. Raiford DS, Sciuto AM, **Mitchell MC**. Effects of vasopressor hormones and protein kinase C agonists/antagonists on efflux of glutathione and permeability of tight junctions in the perfused rat liver. *Am. J. Physiol.* 1991; 261:G578-84.
31. Mezey E, Caballeria J, **Mitchell MC**, Pares A, Herlong HF, Rodes J. Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: A randomized controlled trial. *Hepatology* 1991; 14:1090-96.
32. Blumenthal RS, Flinn IW, Proske O, Jackson DG, Tena RG, **Mitchell MC** and Feldman AM. Effects of chronic ethanol exposure on cardiac receptor-adenyl cyclase coupling: studies in cultured chick myocytes and ethanol fed rats. *Alcoholism: Clin. Exp. Res.* 1991; 15:1077-1083.
33. Klein AS, Savader S, Burdick JF, Fair J, **Mitchell M**, Colombani P, Perler B, Osterman F and Williams GM. Reduction of morbidity and mortality from biliary complications after liver transplantation. *Hepatology* 1991; 14:818-23.
34. Westra WH, Hruban RH, Bauthman KL, Olson JL, Porterfield JK, **Mitchell MC** and Hutchins GM. Progressive hemochromatotic cardiomyopathy despite reversal of iron deposition after liver transplantation. *Am J Clin Path* 1993; 99:39-44.
35. Risby TH, Maley W, Scott RPW, Bulkley GB, Kazui M, Sehnert SS, Schwarz KB, Potter J, Mezey E, Klein AS, Colombani P, Fair J, Merritt WT, Beattie C, **Mitchell MC**, Williams GM, Perler BA, Donham RT and Burdick JF. Evidence for free radical-mediated lipid peroxidation at reperfusion of human orthotopic liver transplants. *Surgery* 1994; 115:94-101.
36. Venbrux AC, Mitchell SE, Savader SJ, Lund GB, Trerotola SO, Newman JS, Klein AS, **Mitchell MC**, Rosch J, Uchida BT and Osterman FA, Jr. Long-term results with the use of metallic stents in the inferior vena cava for treatment of Budd-Chiari syndrome. *J. Vascular Interventional Radiology* 1994; 5:411-416.
37. Dienstag JL, Schiff ER, **Mitchell MC**, Casey DE, Gitlin N, Lissoos T, Gelb LD, Condreay L, Crowther L, Rubin M and Brown N. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy. *Hepatology* 1999; 30 (4):1082-87.

38. Johnson BA, Messing RO, Charness ME, Crabbe JC, Goldman MS, Harris A, Kranzler HR, **Mitchell MC**, Nixon SJ, Riley EP, Schuckit MA, Sher KJ, Thomas JD. Should the reorganization of addiction-related research across all the National Institutes of Health be structural: The devil is truly in the details. *Alcoholism: Clinical and Experimental Research* 2011;35:572-80.
39. **Mitchell MC**, Memisoglu A, Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. *J.Stud. Alcohol Drugs*, 2012; 73:991-997.
40. Thompson CC, Chand B, Chen YK, DeMarco DC, Miller L, Schweitzer M, Rothstein RI, Lautz DB, Slattery J, Ryan MB, Brethauer SB, Schauer P, **Mitchell MC**, Starpoli A, Haber GB, Catalano MF, Edmundowicz S, Fagnant AM, Kaplan LM, Roslin MS. Endoscopic suturing for transoral outlet reduction increases weight loss after Roux-en-Y Gastric Bypass. *Gastroenterology* 2013; 145:129-137.
41. Worthington MT, Antonik LJ, Goldwater DR, Lees JP, Wilhelm-Ogunbiyi K, Borkett KM, **Mitchell MC**. A Phase Ib, Dose-Finding Study of Multiple Doses of Remimazolam (CNS 7056) in Volunteers Undergoing Colonoscopy. *Anesthesia and Analgesia* 2013; 117:1093-1100.
42. **Mitchell MC**, Teigen E, Ramchandani VA. Absorption and peak blood alcohol concentrations after drinking beer, wine or spirits. *Alcoholism: Clinical Experimental Research* 2014; 38:1200-1204.
43. Yeluru A, Cuthbert JA, Casey LC, **Mitchell MC**. Alcoholic hepatitis: Risk factors, pathogenesis and approach to treatment. *Alcoholism: Clinical Experimental Research* 2016; 40:246-255.
44. Crabb DW, Bataller R, Chalasani N, Kamath PS, Lucey M, Mathurin P, McClain C, McCullough A, **Mitchell MC**, Morgan TR, Nagy L, Radaeva S, Sanyal A, Shah V, and Szabo G, on behalf of the NIAAA Alcoholic Hepatitis Consortia. Standard definitions and common data elements for clinical trials in humans with alcoholic hepatitis: 2016 Position Statement from the NIAAA-funded Alcoholic Hepatitis Consortia. *Gastroenterology* 2016; 150:785-90.
45. **Mitchell MC**, Friedman LS, McClain CJ. AGA Clinical Practice Update: The role of glucocorticoids and pentoxifylline in the management of severe alcoholic hepatitis. *J Clin Gastro Hepatol*; 2017; 15:5-12.
46. Aday AW, **Mitchell MC**, Casey LC. Alcoholic hepatitis: Current trends in management. *Current Opinions in Gastroenterology* 2017; 33:142-148.
47. Jia L, Chang X, Qian S, Liu C, Lord CC, Ahmed N, Lee C, Lee S, Gautron L, **Mitchell MC**, Horton JD, Scherer PE, Elmquist JK. Hepatocyte toll-like receptor 4 deficiency protects against alcohol-induced fatty liver disease. *Molecular Metabolism* 2018; 14:121-129. doi: 10.1016/j.molmet.2018.05.015.
48. Saha B, Tornai D, Kodys K, Adejumo A, Lowe P, McClain C, **Mitchell M**, McCullough A, Srinivasan D, Kroll-Desrosieers A, Radaeva S, Szabo G. Biomarkers of macrophage activation and immune danger signals predict clinical outcomes in alcoholic hepatitis. *Hepatology* 2019:1134-49. <https://doi.org/10.1002/hep.30617>,
49. Vatsalya V, Cave MC, Kong M, Gobejishvili L, Falkner KC, Craycroft J, **Mitchell M**, Szabo G, McCullough A, Dasarathy S, Radaeva S, Barton B, McClain CJ. Keratin 18 is a diagnostic and prognostic factor for acute alcoholic hepatitis. *Clin Gastroenterol Hepatol* 2020; 18:2046-54. <https://doi: 10.1016/j.cgh.2019.11.050>, Epub Dec 4, 2019.
50. **Mitchell MC**, Kerr T, Herlong HF. Current management and future treatment of alcoholic hepatitis. *Gastroenterology & Hepatology* 2020; 16:178-189.

51. Fan X, McCullough RL, Huang E, Bellar A, McClain CJ, **Mitchell M**, McCullough AJ, Radaeva S, Barton B, Szabo G, Dasarathy S, Rotroff DM and Nagy LE. Diagnostic and Prognostic Significance of Complement in Patients with Alcohol-associated hepatitis. *Hepatology* 2021 Mar;73(3):983-997. doi: 10.1002/hep.31419. Epub 2020 Nov 22. PMID: 32557728
52. Dasarathy S, **Mitchell MC**, Barton B, McClain CJ, Szabo G, Nagy LE, Radaeva S, McCullough AJ. Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis. *Contemporary Clinical Trials* 2020; 96:106094. doi:10.1016/j.cct.2020.106094. Epub 2020 Jul 31. PMID: 32739495
53. Lazo M, Bilal U, **Mitchell MC**, Potter J, Hernaez R, Clark JM. Interaction between alcohol consumption and *PNPLA3* variant in the prevalence of hepatic steatosis in the U.S. population. *Clin Gastro Hepatol* 2020; *Gastroenterol Hepatol.* 2020 Aug 31:S1542-3565(20)31213-1. doi: 10.1016/j.cgh.2020.08.054.
54. Miyata T, Wu X, Fan X, Huang E, Sanz-Garcia C, Ross CKC, Roychowdhury S, Bellar A, McMullen MR, Dasarathy J, Allende DS, Caballeria J, Sancho-Bru P, McClain CJ, **Mitchell M**, McCullough AJ, Radaeva S, Barton B, Szabo G, Dasarathy S, Nagy LE. Differential role of MLKL in alcohol-associated and non-alcohol-associated fatty liver diseases in mice and humans. *JCI Insight.* 2021 Feb 22;6(4):e140180. doi: 10.1172/jci.insight.140180. PMID: 33616081
55. Cotter TG, Wang J, Lieber SR, Odenwald MA, Rich NE, Marrero JA, Singal AG, **Mitchell MC**, Aronsohn A, Charlton M, Fung J. "Raising HOPE": Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era. *Transplant Direct.* 2021 Jun 8;7(7):e707. doi: 10.1097/TXD.0000000000001154
56. Helsley RN, Miyata T, Kadam A, Varadharajan V, Sangwan N, Huang EC, Banerjee R, Brown AL, Fung KK, Massey WJ, Neumann C, Orabi D, Osborn LJ, Schugar RC, McMullen MR, Bellar A, Poulsen K, Kim A, Pathak V, Mrdjen M, Anderson JT, Willard B, McClain CJ, **Mitchell M**, McCullough AJ, Radaeva S, Barton B, Szabo G, Dasarathy S, Garcia-Garcia JC, Rotroff DM, Allende DS, Wang Z, Hazen SL, Nagy LE, Brown JM. Gut microbial trimethylamine is elevated in alcohol-associated hepatitis and contributes to ethanol-induced liver injury in mice. *eLife* 2022; 11:e76554 doi: 10.7554/eLife.76554
57. Szabo G, **Mitchell MC**, McClain CJ, Dasarathy S, Barton B, McCullough AJ, Nagy LE, Droll-Desrosiers, A, Tornai D, Hyesung AM, Radaeva S, Holbein B, Casey L, Cuthbert J. IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis. *Hepatology* 2022; published online 27 March 2022; <https://doi.org/10.1002/hep.32478>

Reviews, Chapters, Monographs and Editorials

Invited reviews:

1. **Mitchell MC.** Alcohol-induced impairment of central nervous system function: behavioral skills involved in driving. *J. Stud. Alcohol Supplement* 1985; 10 S109-S116.
2. **Mitchell MC.** Chronic hepatitis B. *Current Treatment Options in Infectious Diseases* 2001; 3:431-5.
3. Aday AW, **Mitchell MC.** Food for thought: Importance of nutrition in alcoholic hepatitis. *Nutrition issues in Gastroenterology; Practical Gastroenterology* 2018; 173:30-36.

Editorials:

1. **Mitchell MC**, Mezey E. Ethanol and amino acid uptake. (Editorial) *Hepatology* 7:390-392, 1987.

2. Johnson BA, Messing RO, Charness ME, Crabbe JC, Goldman MS, Harris A, Kranzler HR, **Mitchell MC**, Nixon SJ, Riley EP, Schuckit MA, Sher KJ, Thomas JD. How should addiction-related research at the National Institutes of Health be reorganized? *Front. Psychiatry* **2**:2. doi: 10.3389/fpsy.2011.00002
3. **Mitchell MC** and Maddrey WC. Changing times in liver transplantation for alcohol-associated liver disease. *JAMA Int Med.* 2019; 179:348-50.
4. McClain CJ, Vatsalya V, **Mitchell MC**. Keratin-18: Diagnostic, prognostic and theragnostic for alcohol-associated hepatitis. *Am J Gastroenterol.* 2021 Jan 1;116(1):77-79. doi:10.14309/ajg.0000000000001042.PMID: 33306505

Books/Textbooks

1. **Mitchell MC**, Schenker S. Hepatic drug metabolism and drug-induced liver disease. *In*: Gitnik G, ed. Current Hepatology, Vol 3. John Wiley and Sons, New York. 1983. pp. 205-239.
2. **Mitchell MC**. Alcohol-induced impairment of central nervous system function: behavioral skills involved in driving. *J. Stud. Alcohol Supplement* 1985; 10 S109-S116.
3. **Mitchell MC**. Hepatic drug metabolism. *In*: Bayless TM, ed. Current Therapy in Gastroenterology and Liver Disease. B.C. Decker, Inc., Toronto. 1983 pp. 387-391.
4. **Mitchell MC**. Alcoholism and associated medical disorders. *In*: Harvey AM, Johns R, McKusick VA, and Ross R, eds. The Principles and Practice of Medicine. Appleton Century Crofts, Inc. Norwalk, Conn, 1984, pp. 1483-1489.
5. **Mitchell MC**. Hepatic drug metabolism. *In*: Bayless TM, Brain RM, Cherniack RM, eds. Current Therapy in Internal Medicine., B.C. Decker, Inc., Toronto. 1984. pp. 680-685.
6. **Mitchell MC**. Hepatic drug metabolism. *In*: Bayless TM, Brain RM, Cherniack RM, eds. Current Therapy in Internal Medicine., B.C. Decker, Inc., Toronto. 1984. pp. 680-685.
7. **Mitchell MC**, Mezey E. Alcoholism and Associated Medical Disorders. *In*: Harvey AM, Johns R, McKusick VA, and Ross R, eds. The Principles and Practice of Medicine. Appleton Century Crafts, Inc. Norwalk Conn, 1988, pp. 1181-1186.
8. **Mitchell MC**. Focal and circulatory disorders of the liver. *In*: Harvey AM, Johns R, McKusick VA, and Ross R, eds. The Principles and Practice of Medicine. Appleton Century Crafts, Inc. Norwalk, Conn, 1988, pp. 854-857.
9. Herlong HF, **Mitchell MC**. Viral and drug-induced hepatitis. *In*: Harvey AM, Johns R, McKusick VA, and Ross R, eds. The Principles and Practice of Medicine. Appleton Century Crafts, Inc. Norwalk, Conn, 1988, pp. 841-847.
10. **Mitchell MC**. Alcoholic liver disease. *In*: Bayless TM, ed. Current Therapy in Gastroenterology and Liver Disease 3rd Edition. B.C. Decker, Inc, Toronto, 1989, pp. 438-41.
11. **Mitchell MC**. Alcohol and Nutrition. *In*: Brown ML, ed. Present Knowledge and Nutrition. International Life Sciences Institute, Washington, D.C., 1990, pp. 457-62.

12. Raiford DS, **Mitchell MC**. Disorders of drug disposition. *In*: Rector WG, ed. Complications of Chronic Liver Disease. Mosby Yearbook, St. Louis, 1992, pp. 238-253.
13. **Mitchell MC**, Raiford DS, Mallat A. Effects of ethanol on hepatic glutathione metabolism and glutathione-dependent enzymes. *In*: Watson RR, ed. The Liver: Changes Caused by Drugs of Abuse. Humana Press, Clifton, NJ., 1991, pp. 169-194.
14. **Mitchell MC**. Pathophysiology of alcoholic liver damage. *In*: Kaplowitz N, ed. Liver and Biliary Diseases. Williams and Wilkins, Baltimore, 1992, pp. 98-117.
15. **Mitchell MC**. Viral hepatitis, drug-induced and alcoholic liver disease. *In*: Harvey AM, Johns R, McKusick VA, Owens A, Ross RS (eds). The Principles and Practice of Medicine. Appleton and Lange, Norwalk, 1995.
16. **Mitchell MC**. Drug-induced liver damage. *In*: Bayless TB, ed. Current Therapy in Gastroenterology and Liver Disease 4th Edition. Mosby, St. Louis, 1994, pp. 554-558.
17. **Mitchell, MC**. Budd-Chiari syndrome and other vascular disorders. Handbook of Liver Disease. Churchill-Livingstone, 1998, pp.267-275.
18. **Mitchell, MC**. Alcoholism and related disorders. *In*: Bayless, TB and Diehl AM, eds. Current Therapy in Gastroenterology and Liver Disease 5th Edition. Mosby, St. Louis, 2005.
19. **Mitchell, MC** and Herlong, HF. Abdominal pain and irritable bowel syndrome. *In*: Barker, LR, Burton JR, Zieve PD, eds. Principles of Ambulatory Medicine. Lippincott, Williams and Wilkins, Philadelphia, 2006, pp. 670-687.
20. **Mitchell, MC** and Herlong, HF. Selected gastrointestinal problems: Constipation and diarrhea. *In*: Barker, LR, Burton JR, Zieve PD, eds. Principles of Ambulatory Medicine. Lippincott, Williams and Wilkins, Philadelphia, 2006, pp.687-704.
21. **Mitchell, MC** and Herlong, HF. Selected gastrointestinal problems: GI bleeding, colorectal cancer screening, diverticular disease and ostomy care. *In*: Barker, LR, Burton JR, Zieve PD, eds. Principles of Ambulatory Medicine. Lippincott, Williams and Wilkins, Philadelphia, 2006, pp.705-716.
22. Herlong, HF and **Mitchell, MC**. Disorders of the esophagus: Dysphagia, non-cardiac chest pain and gastroesophageal reflux. *In*: Barker, LR, Burton JR, Zieve PD, eds. Principles of Ambulatory Medicine. Lippincott, Williams and Wilkins, Philadelphia, 2006, pp.645-658.
23. Herlong, HF and **Mitchell, MC**. Peptic ulcer disease. *In*: Barker, LR, Burton JR, Zieve PD, eds. Principles of Ambulatory Medicine. Lippincott, Williams and Wilkins, Philadelphia, 2006, pp.659-670.
24. **Mitchell, MC**. Hepatic Encephalopathy. *In*: Current Therapy in Surgery. Cameron, JC, eds. Mosby, Elsevier. Philadelphia, 2008:396-399.
25. Herlong HF and **Mitchell MC**. Evaluation of liver enzymes. *In*: Schiff E, Maddrey WC, Sorrell MF, eds. Schiff's Diseases of the Liver. Wiley-Blackwell, Oxford, 2012, pp.17-43.
26. **Mitchell MC**. Budd-Chiari syndrome and other vascular disorders. *In*: Friedman LS and Keefe E. Handbook of Liver Disease. Elsevier Saunders, Philadelphia, 2012, pp. 259-267

27. Lazo M and **Mitchell MC**. Epidemiology and risk factors for alcoholic liver disease. *In*: Szabo G and Chalassani N. Alcoholic and non-alcoholic fatty liver disease. Springer International Publishing, 2016, pp. 1-20.
28. **Mitchell MC** and Szabo G. Alcoholic liver disease. *In*: Schiff E, Maddrey WC, Sorrell MF, eds. Schiff's Diseases of the Liver. Wiley-Blackwell, Oxford, 2017, pp. 701-739.

Case Reports

1. **Mitchell MC**, Arregui A, Boitnott J, Maddrey WC. Granulomatous hepatitis with carbamazepine therapy. *Amer. J. Medicine* 1981; 71:733-735.
2. Mullin GE, Greenson JK, **Mitchell MC**. Fulminant hepatic failure after ingestion of sustained release nicotinic acid. *Ann. Int. Med.* 1989; 111:253-255.
3. Schweitzer MA, Steele K, Mitchell MC, Okolo P. Transoral endoscopic closure of a gastric fistula. *Surg. Obes. Relat. Dis.* 2009; 5:283-284.

Letters to the Editor

Letters/Correspondence:

1. Speeg KV, Christian DC, **Mitchell MC**. Ranitidine and acetaminophen hepatotoxicity. (Letter) *Ann. Int. Med.* 100:315, 1984.
2. **Mitchell MC**, Potter JJ, Mezey E. Ethanol and H₂-receptor antagonists. (Letter) *Hepatology* 5:909, 1985.

Non-peer reviewed scientific or medical publications/materials in print or other media

Other media:

1. **Mitchell, MC**, editor. Signs and symptoms in internal medicine. Pocket Medicine, an electronic book specifically for PDA's. 2003.